金融界2025年5月12日消息，中欧医疗创新股票A(006228) 最新净值1.1755元，下跌3.18%。该基金近1个 月收益率2.39%，同类排名515|702；近3个月收益率12.51%，同类排名26|701；今年来收益率13.05%， 同类排名48|696。 来源：金融界 中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(20 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has seen a decline in its net value and varying returns over different time frames [1] - As of May 12, 2025, the latest net value of the fund is 1.4849 yuan, reflecting a decrease of 1.90% [1] - The fund's performance over the past month shows a return of 0.75%, ranking 1780 out of 1948 in its category; over the past three months, it has a return of -0.05%, ranking 956 out of 1931; and since the beginning of the year, it has a return of -1.56%, ranking 1595 out of 1919 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan, managed by fund manager Ge Lan [1]

Group 1 - The core viewpoint highlights the evolution of Chinese innovative pharmaceutical companies over the past decade, transitioning from rule followers to challengers and finally to rule makers, with 2015 marking the start of the shift from generic to innovative drugs [1] - The Hong Kong innovative drug sector has seen a significant reduction in valuation, with the Hong Kong innovative drug index's price-to-earnings ratio dropping from 64 times on February 21 to 25 times on May 9, indicating a strong value proposition for current investments [1] - On May 12, the Hong Kong market experienced a V-shaped rebound in the innovative drug sector, with notable gains in stocks such as Far East Pharmaceutical rising over 7%, and others like Rongchang Bio and Dongyangguang Changjiang Pharmaceutical increasing over 2% [1] Group 2 - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry, benefiting from trends such as AI-enabled drug development and the introduction of a new insurance category for high-priced innovative drugs [2] - Pacific Securities forecasts a recovery in global healthcare financing, projecting a 1% year-on-year increase to $58.2 billion in 2024, reflecting restored market confidence [2] - The ongoing rise of the domestic innovative drug index is expected to enhance the investment environment for innovative drug research and development companies, supported by a favorable macroeconomic backdrop including a loosening of liquidity due to the Federal Reserve's interest rate cuts [2]

医疗服务 执业证书编号：S0740519040001 Email：zhujq@zts.com.cn 分析师：崔少煜 执业证书编号：S0740522060001 Email：cuisy@zts.com.cn | 基本状况 | | | --- | --- | | 总股本(百万股) | 864.95 | | 流通股本(百万股) | 693.26 | | 市价(元) | 44.79 | | 市值(百万元) | 38,741.05 | | 流通市值(百万元) | 31,051.18 | 泰格医药（300347.SZ） 证券研究报告/公司点评报告 2025 年 05 月 11 日 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：祝嘉琦 | | 营业收入（百万元） | 7384.04 | 6603.12 | 7110.99 | 7878.95 | 8907.31 | | 执业证书编号 ...

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, suggesting a potential for growth in 2025 due to favorable macroeconomic factors and the recovery of public fund allocations to the sector [11]. Core Insights - The pharmaceutical sector is currently undervalued, with public fund allocations at a low point, but is expected to recover, driven by large-scale products and innovations [11]. - The report highlights a shift in the innovative drug sector from quantity to quality, emphasizing the importance of differentiated products and international pipelines [11]. - In the medical device sector, there is a notable recovery in bidding volumes, particularly for imaging equipment, and a push for home medical devices supported by government subsidies [11]. - The report identifies a significant growth opportunity in the CXO and life sciences services sectors, with expectations of a rebound in domestic financing and a trend towards consolidation [11]. - The traditional Chinese medicine sector is expected to see growth driven by unique essential medicines and state-owned enterprise reforms [11]. Summary by Sections Market Review - The medical device index increased by 0.98%, underperforming the CSI 300 index by 1.03 percentage points, ranking 26th among 30 sectors [8]. - The top ten stocks by growth included JinHao Medical and ChangShan Pharmaceutical, while the bottom ten included ST HuLuWa and YongAn Pharmaceutical [8]. Medical Device Updates - The report notes a significant increase in medical device bidding volumes, with a year-on-year growth of 67.49% in Q1 2025, indicating a strong recovery [20]. - Imaging devices, particularly ultrasound, CT, and DR, are highlighted as the most sought-after categories in procurement [25]. - The report anticipates a surge in procurement activities in county-level medical communities, driven by government support policies [29]. Innovative Drugs - The report emphasizes the growth potential in the innovative drug sector, particularly for companies like BeiGene and Innovent Biologics, which are expected to benefit from their differentiated product pipelines [11]. - The focus on autoimmune diseases is noted as a new growth curve for companies like Nuo Cheng Jian Hua, with significant market potential [37]. Medical Services - The report suggests that the medical service sector will benefit from anti-corruption measures and the expansion of commercial insurance, enhancing the competitiveness of private medical institutions [11]. Blood Products - The blood products sector is expected to grow due to relaxed approval processes for plasma stations and increased demand post-pandemic, with companies like TianTan Biological and BoYa Biological highlighted as key players [11].

Market Overview - The Hong Kong stock market showed a general upward trend, with the Hang Seng Index rising by 0.37%, the Hang Seng China Enterprises Index increasing by 0.7%, and the Hang Seng Tech Index up by 0.56%, marking a six-day consecutive rise for the Hang Seng Index [1][2]. Sector Performance - Major technology stocks maintained an upward trend, with Meituan and Tencent both rising nearly 2%, Xiaomi up 1.4%, while Baidu fell nearly 3% and NetEase showed a decline [2]. - Defense stocks surged due to escalating tensions in the India-Pakistan conflict, with AVIC Industry and China Shipbuilding Defense both rising over 6% [4][5]. - Bitcoin briefly surpassed $99,000, leading to a significant rise in cryptocurrency-related stocks, with New Fire Technology Holdings soaring nearly 20% [2]. - The automotive sector saw strong performance, with companies like Geely, Li Auto, and Great Wall Motors all rising over 4% [8]. - Gaming stocks also performed well, with Huicai Holdings increasing over 13% and Sands China up over 1% [9]. - Consumer electronics and home appliance stocks were active, with JS Global Life rising over 3% and TCL Electronics up over 2% [10]. - Agricultural stocks increased, with China Heartlink Fertilizer and First Tractor Company both rising over 3% [11]. - Power sector stocks strengthened, with Harbin Electric rising over 4% [12]. - Steel stocks experienced significant declines, with Find Steel Group dropping over 12% [13]. Individual Stock Highlights - AVIC Industry closed at HKD 4.09, up 6.23%, while China Shipbuilding Defense closed at HKD 10.92, up 6.02% [6]. - Pharmaceutical outsourcing stocks were active, with Zhaoyan New Drug rising over 5% [7]. - The debut of "Hushang Aunt" saw a significant increase of 40%, closing at HKD 158.4 per share, with a total market capitalization of HKD 16.225 billion [16]. - Southbound funds recorded a net sell of HKD 2.385 billion, with the Shanghai-Hong Kong Stock Connect seeing a net sell of HKD 1.097 billion [18]. Future Outlook - Zhejiang International expresses caution regarding the short-term fundamentals and capital flows in the Hong Kong market, while maintaining a cautiously optimistic view on the medium-term outlook [20]. - The company recommends focusing on sectors that are relatively prosperous and benefit from policy support, such as automotive, consumer, electronics, and technology, as well as low-valuation state-owned enterprises [20].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 HANGZHOU TIGERMED CONSULTING CO., LTD. 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年5月7日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞增玉先生；獨立非執行董事為廖啟宇先生、袁華剛先 ...

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 7, 2025, the latest net value of the fund is 1.5753 yuan, reflecting a decrease of 1.28%. The fund's return over the past month is -2.61%, ranking 4118 out of 4649 in its category. Over the past three months, the return is 4.24%, ranking 1179 out of 4597, and since the beginning of the year, the return is 1.73%, ranking 2415 out of 4556 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University in the United States. She has held various research and fund management positions before becoming the manager of the China Europe Medical Health Mixed Fund [2]

为进一步加强与投资者的互动交流，杭州泰格医药科技股份有限公司（以下简称"公 司"）将参加由浙江证监局指导，浙江上市公司协会主办，深圳市全景网络有限公司承办的 "2025年浙江辖区上市公司投资者网上集体接待日暨2024年度业绩说明会"，现将相关事项 公告如下： 本次活动将采用网络远程的方式举行，投资者可登录 " 全景路演" 网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP，参与本次互动 交流，活动时间为2025年5月13日（周二）15：00-17：00。届时公司高管将在线就公司业 绩、公司治理、发展战略、经营状况和可持续发展等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 杭州泰格医药科技股份有限公司董事会 二〇二五年五月七日 证券代码：300347 证券简称：泰格医药 公告编码（2025）025 号 杭州泰格医药科技股份有限公司 关于参加 2025 年浙江辖区上市公司投资者 网上集体接待日暨 2024 年度业绩说明会的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 FF301 II. 已發行股份及/或庫存股份變動 呈交日期: 2025年5月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 741,823,770 | RMB | | 1 RMB | | 741,823,770 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 741,823,770 | RMB | | 1 RMB | | 741,823 ...